NCT03766867 is a Phase 2 clinical trial of Vortioxetine infusion 25 mg in Major Depressive Disorder, sponsored by H. Lundbeck A/S.

Who is sponsoring NCT03766867?

NCT03766867 is sponsored by H. Lundbeck A/S.

What drugs are being tested in NCT03766867?

Interventions in NCT03766867: Vortioxetine infusion 25 mg, Vortioxetine tablets 10 mg/day, Placebo infusion, Placebo tablets.

What condition does NCT03766867 study?

NCT03766867 studies Major Depressive Disorder.

Is NCT03766867 still recruiting?

NCT03766867 is currently completed. Last updated 29 August 2019.

Last reviewed 2019-08-29 · How we verify

NCT03766867

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

Completed Phase 2 Last updated 29 August 2019

What this trial tests

Phase 2 trial testing Vortioxetine infusion 25 mg in Major Depressive Disorder in 80 participants. Completed in 28 August 2019.

Timeline

3 December 2018

Primary endpoint
31 July 2019

28 August 2019

Quick facts

Lead sponsor	H. Lundbeck A/S
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	80
Start date	3 December 2018
Primary completion	31 July 2019
Estimated completion	28 August 2019
Sites	13 locations across Estonia, Bulgaria, Latvia

Drugs / interventions tested

Vortioxetine infusion 25 mg — full drug profile →
Vortioxetine tablets 10 mg/day — full drug profile →
Placebo infusion — full drug profile →
Placebo tablets — full drug profile →

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

H. Lundbeck A/S — full company profile →

Who can join

Adults 18 to 65, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of vortioxetine given as a single intravenous dose of 25 mg at initiation of an oral vortioxetine regimen of 10 mg/day for 7 days

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study.
Rancans E, Zambori J, Dalsgaard M, Baayen C, et al · · 2020 · cited 8× · PMID 32784346 · DOI 10.1097/yic.0000000000000326

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other H. Lundbeck A/S trials

Trials by the same sponsor.

NCT07514858 — A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations · Phase 2 · not yet recruiting
NCT07513441 — A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD) · Phase 1 · not yet recruiting
NCT06701526 — A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications · Phase 4 · active not recruiting
NCT06706622 — A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) · Phase 3 · active not recruiting
NCT06557850 — A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03766867 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lundbeck A/S
Last refreshed: 29 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03766867.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing